ANGLE plc (LSE:AGL) Confirms New Adviser Appointment

Highlights

• ANGLE plc (LSE:AGL) appoints Cavendish Capital Markets Limited as Nominated Adviser and Sole Broker

• The company continues to advance its Parsortix® PC1 System in clinical oncology and research applications

• Recent corporate changes highlight ongoing activity across FTSE AIM 100 Index listed companies

ANGLE plc (LSE:AGL), a biotechnology enterprise specialising in circulating tumour cell (CTC) technology, confirmed the appointment of Cavendish Capital Markets Limited as its new Nominated Adviser and Sole Broker. The announcement, released through the London Stock Exchange’s RNS service, underscores the company’s alignment with the advisory and broking services required for its listing on the FTSE AIM 100 Index. ANGLE plc operates within the liquid biopsy segment, offering solutions designed to enable cancer diagnostics, research, and clinical applications through its FDA-cleared Parsortix® PC1 System.

What recent announcement was made by ANGLE plc?

ANGLE plc disclosed through an official regulatory filing that Cavendish Capital Markets Limited has been appointed as both Nominated Adviser (NOMAD) and Sole Broker to the company. The change took effect immediately upon release of the statement. A company listed on AIM, such as ANGLE, is required to have a NOMAD, whose responsibility is to guide the company on compliance with the AIM Rules for Companies.

The announcement listed Cavendish Capital Markets Limited personnel responsible for corporate finance and broking, as well as individuals dedicated to life sciences and corporate broking roles. ANGLE’s board members, including Chief Executive Andrew Newland and Finance Director Ian Griffiths, were named as key contacts for the company.

Why is the appointment of a NOMAD significant for AIM companies?

Companies admitted to trading on the AIM segment of the ftse are required to retain a Nominated Adviser. The NOMAD performs a critical role in assessing whether the company is appropriate for AIM, advising on regulatory requirements, and maintaining compliance with market rules.

For ANGLE plc, appointing Cavendish Capital Markets Limited represents continuity in ensuring oversight and support in meeting its obligations as an AIM-listed entity. Furthermore, acting as Sole Broker, Cavendish assumes responsibility for liaising with the market and providing services related to the trading of the company’s shares.

What does ANGLE plc specialise in?

ANGLE plc describes itself as a world-leading liquid biopsy enterprise. Its technology focuses on harvesting circulating tumour cells (CTCs) from a simple blood sample, offering clinical and research organisations a non-invasive means of analysing cancer progression and treatment. The company’s flagship product, the Parsortix® PC1 System, is FDA cleared and patent protected, allowing complete downstream analysis including whole cell imaging, proteomic profiling, genomic sequencing, and transcriptomic evaluation.

The company has developed two commercial branches. The first involves diagnostic products such as the Parsortix® system and related consumables and assays. The second branch is centred on clinical services, offered through GCLP-compliant laboratories, where the company provides assay development and clinical trial testing for pharmaceutical clients.

How is the Parsortix® PC1 System positioned in clinical oncology?

The Parsortix® PC1 System is positioned as a liquid biopsy solution with utility in both research and clinical settings. By isolating intact circulating tumour cells from blood, it enables comprehensive analysis that goes beyond traditional biopsy methods. This facilitates insights into tumour heterogeneity, treatment resistance, and disease monitoring.

Peer-reviewed publications, numbering over one hundred, have highlighted the system’s ability to deliver reproducible and clinically relevant results. These studies span applications in drug development, translational research, and oncology diagnostics. The system’s validation across these contexts demonstrates its role in advancing cancer-related clinical services and technologies.

Which advisory firms were included in the announcement?

The announcement listed three principal organisations connected with ANGLE plc:

• Cavendish Capital Markets Limited: Serving as the new Nominated Adviser and Sole Broker.

• FTI Consulting: Providing communications and public relations support across the UK and US.

• ANGLE plc leadership team: Chief Executive Andrew Newland and Finance Director Ian Griffiths named as internal contacts.

These parties reflect the combined efforts of corporate advisory, investor communications, and executive leadership in shaping the company’s external relations and compliance framework.

What does the change of adviser reveal about corporate governance?

Corporate governance for AIM-listed companies requires alignment with regulatory obligations and market transparency. The appointment of Cavendish Capital Markets Limited highlights the role of external advisers in ensuring these obligations are met. Such changes are disclosed publicly through the London Stock Exchange’s RNS service, emphasising the importance of transparent reporting.

For ANGLE plc, this move is presented as a seamless transition, with an immediate effective date, ensuring there is no disruption to the company’s ability to comply with AIM requirements.

What role does FTI Consulting play in the announcement?

FTI Consulting was listed as the public relations and communications partner for ANGLE plc. The firm provides services designed to ensure the company’s messaging reaches stakeholders in a clear and structured manner. Contact details for UK and US representatives were included in the release, illustrating the company’s international communications strategy.

This engagement with a specialist consultancy underscores the role of external communications partners in maintaining transparency and structured messaging for listed companies.

How does ANGLE plc align with the FTSE AIM UK 50 INDEX segment?

ANGLE plc is admitted to trading on AIM, a market within the London Stock Exchange designed for growth-oriented companies. The FTSE AIM UK 50 INDEX and FTSE AIM 100 Index track the performance of companies listed on AIM, offering visibility into this segment of the market.

By operating within the AIM framework, ANGLE plc is part of a wider ecosystem of life sciences, technology, and innovation-driven enterprises. Its appointment of a new NOMAD reflects the governance processes that underpin AIM’s regulatory environment.

What notes were included for editors?

The announcement’s “Notes for editors” section provided a summary of ANGLE plc’s operations and specialisation. It described the company’s role in liquid biopsy, the capabilities of its Parsortix® PC1 System, and its dual commercial focus on diagnostics and clinical services.

Additionally, it highlighted the extensive publication record validating the system and referenced the company’s GCLP-compliant laboratories. Links to ANGLE’s website were provided for further details, including a glossary of frequently used terms related to the company’s operations.

What compliance statement accompanied the release?

The release concluded with a standard compliance note from the London Stock Exchange’s RNS service. This explained that RNS is approved by the Financial Conduct Authority as a Primary Information Provider in the United Kingdom. It also stated that terms and conditions apply to the use of the information, along with data processing details relevant to how RNS handles user engagement and compliance.

This ensures clarity regarding the regulatory status of the announcement and the role of RNS in distributing market-sensitive information.

How does ANGLE plc maintain visibility in oncology research?

The visibility of ANGLE plc in oncology research is sustained through publications and partnerships. Over one hundred peer-reviewed papers have documented the capabilities of the Parsortix® PC1 System. These publications have examined areas such as metastatic progression, treatment monitoring, and the biology of circulating tumour cells.

The company’s laboratories also enable bespoke assay development, allowing pharmaceutical clients to integrate CTC-based testing into clinical trials. This contributes to the company’s visibility not only as a product provider but also as a partner in clinical and translational research initiatives.

What corporate services are linked to ANGLE plc’s operations?

The corporate services associated with ANGLE plc extend across compliance, advisory, broking, and communications. Cavendish Capital Markets Limited is tasked with advisory and broking, while FTI Consulting ensures structured communication across multiple regions.

Internally, the company’s executive leadership maintains strategic oversight. These combined services ensure the company’s obligations as an AIM-listed entity are met while supporting the dissemination of its developments in oncology.

How does ANGLE plc reflect activity among LSE-listed biotechnology companies?

The appointment of a new adviser underscores the activity within the biotechnology sector listed on the London Stock Exchange. Companies on AIM, particularly those in life sciences, often engage in corporate transitions related to advisers, funding, and partnerships. Such announcements form part of the wider landscape of updates in the ftse 350 and AIM indices, reflecting the dynamism of this sector.

ANGLE plc, as a biotechnology company with an FDA-cleared system, highlights the contribution of AIM-listed firms to healthcare innovation and oncology solutions.

How is downstream integrated into ANGLE plc’s platform?

The Parsortix® PC1 System enables downstream analysis of captured circulating tumour cells, including imaging, proteomic assessment, and genomic sequencing. These analyses are essential in understanding tumour biology and monitoring therapeutic responses.

This integration positions ANGLE plc as a provider of comprehensive platforms that extend beyond CTC capture to a full spectrum of analytical outputs. Such integration reflects the company’s role in bridging diagnostics with advanced research in oncology.

What key contacts were listed in the announcement?

The announcement listed multiple key contacts for further information:

• ANGLE plc: Andrew Newland, Chief Executive; Ian Griffiths, Finance Director.

• Cavendish Capital Markets Limited: Geoff Nash, Isaac Hooper (Corporate Finance), Sunila de Silva (Corporate Broking), Nigel Birks (Life Science Specialist).

• FTI Consulting: Simon Conway, Ciara Martin, Sam Purewal, and Matthew Ventimiglia in the US.

These contacts illustrate the structured communication pathways available to stakeholders seeking information regarding the company’s corporate and operational updates.

What wider context does this development highlight within AIM?

The appointment of new advisers highlights the ongoing evolution of companies within AIM, a market segment of the ftse 100 and ftse 350 ecosystem. While AIM companies operate with growth-oriented profiles, they remain subject to regulatory oversight through NOMADs and brokers.

For ANGLE plc, the transition to Cavendish Capital Markets Limited underscores the significance of corporate alignment with advisory institutions in ensuring sustained compliance and visibility within the market.

How does ANGLE plc engage with pharmaceutical clients?

Through its clinical services division, ANGLE plc engages with pharmaceutical clients by offering laboratory services and custom assay development. This allows integration of circulating tumour cell analysis into clinical trials, providing additional data for evaluating therapeutic responses.

The company’s GCLP-compliant laboratories enable it to meet international standards for clinical testing, thereby supporting its role as both a technology provider and a service partner in oncology research.

How do regulatory filings contribute to transparency?

Regulatory filings distributed through RNS contribute to transparency by providing timely disclosure of corporate changes. For AIM-listed entities like ANGLE plc, these filings are a critical mechanism for ensuring the market remains informed of material developments.

The inclusion of contact information, notes for editors, and compliance statements within the announcement demonstrates the structured approach required in maintaining transparency across all market communications.

What role does intellectual property play in ANGLE plc’s technology?

The Parsortix® PC1 System is patent protected, securing ANGLE plc’s intellectual property in the field of circulating tumour cell capture. Intellectual property rights provide legal protection and safeguard the uniqueness of the company’s technology in a competitive biotechnology landscape.

This ensures the company retains exclusivity in developing and commercialising its liquid biopsy platform, reinforcing its position as a leading player within the AIM life sciences sector.

How does ANGLE plc’s laboratory capability enhance its services?

ANGLE’s laboratories operate under Good Clinical Laboratory Practice (GCLP) compliance, enabling it to provide services for assay development and clinical trial testing. Such facilities expand the company’s ability to serve pharmaceutical partners and academic collaborators.

This laboratory capability complements its Parsortix® system by providing a practical setting for the development of customised assays, facilitating wider adoption of CTC-based solutions in oncology.

Why are peer-reviewed publications important for ANGLE plc?

Peer-reviewed publications validate the scientific credibility of ANGLE plc’s platform. By demonstrating reproducibility and clinical relevance across multiple studies, these publications strengthen the system’s acceptance among clinicians, researchers, and pharmaceutical companies.

The large number of publications underscores the platform’s utility across diverse applications in oncology, supporting its reputation within the life sciences community.

How is corporate communication structured in such announcements?

Corporate communication in announcements like ANGLE plc’s adviser change is structured to include the following elements:

• Immediate disclosure of the development.

• Clear identification of corporate contacts and advisers.

• A background section summarising the company’s operations.

• Regulatory compliance notes.

This structure ensures the information is presented in a concise, factual manner suitable for stakeholders within the financial and corporate environment.

How does ANGLE plc’s focus on liquid biopsy reflect broader healthcare trends?

Liquid biopsy represents a broader trend in oncology towards non-invasive diagnostic methods. By focusing on circulating tumour cell capture and analysis, ANGLE plc aligns with this trend, offering tools that can complement or replace traditional tissue biopsies.

The company’s Parsortix® PC1 System reflects the industry’s shift towards technologies that enable real-time monitoring of cancer and improved patient stratification in clinical trials.